An Open-Label Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn’s Disease (Holiday)
Brief description of study
You are being asked to take part in this research study because you have Crohn’s disease and the medical treatments you have tried have not brought you to full remission (clinically and physically symptom-free).
Detailed description of study
If you agree to take part, your participation will last for 6-7 months and will involve 5 study visits each of approximately 60 minutes in length and 3 telephone calls each of approximately 30 minutes in length.
You might be eligible to participate in this trial if:
1. You have Crohn’s Disease
2. You are between the ages of 18-64
3. You have tried multiple therapies with NO relief
4. You failed 8 weeks of:
• Azathioprine
• 6-mercaptopureine
• Methotrexate
• Adalimumab
• Certolizumab
• Golimumab
• Infliximab
• Natalizumab OR
• Vedolizumab
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Inflammatory Bowel Diseases,crohns
-
Age: Between 18 Years - 64 Years
-
Gender: All
Updated on
09 Aug 2022.
Study ID: 823635
